Protective Effect of Resveratrol in an Experimental Model of Salicylate-Induced Tinnitus

Int J Mol Sci. 2022 Nov 16;23(22):14183. doi: 10.3390/ijms232214183.

Abstract

To date, the effect of resveratrol on tinnitus has not been reported. The attenuative effects of resveratrol (RSV) on a salicylate-induced tinnitus model were evaluated by in vitro and in vivo experiments. The gene expression of the activity-regulated cytoskeleton-associated protein (ARC), tumor necrosis factor-alpha (TNFα), and NMDA receptor subunit 2B (NR2B) in SH-SY5Y cells was examined using qPCR. Phosphorylated cAMP response element-binding protein (p-CREB), apoptosis markers, and reactive oxygen species (ROS) were evaluated by in vitro experiments. The in vivo experiment evaluated the gap-prepulse inhibition of the acoustic startle reflex (GPIAS) and auditory brainstem response (ABR) level. The NR2B expression in the auditory cortex (AC) was determined by immunohistochemistry. RSV significantly reduced the salicylate-induced expression of NR2B, ARC, and TNFα in neuronal cells; the GPIAS and ABR thresholds altered by salicylate in rats were recovered close to their normal range. RSV also reduced the salicylate-induced NR2B overexpression of the AC. These results confirmed that resveratrol exerted an attenuative effect on salicylate-induced tinnitus and may have a therapeutic potential.

Keywords: NMDA receptor; excitotoxicity; resveratrol; salicylate; tinnitus.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Humans
  • Neuroblastoma*
  • Rats
  • Rats, Sprague-Dawley
  • Resveratrol* / pharmacology
  • Resveratrol* / therapeutic use
  • Salicylates / pharmacology
  • Tinnitus* / chemically induced
  • Tinnitus* / drug therapy
  • Tinnitus* / pathology
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Resveratrol
  • Salicylates
  • Tumor Necrosis Factor-alpha

Grants and funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021RIF1A1060212).